Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...
Veppanu represents a scientific milestone as the first-ever proteolysis-targeting chimera (PROTAC) to receive FDA approval.
Vepdegestrant becomes the first FDA-approved heterobifunctional protein degrader (PROTAC) in breast cancer, targeting ER ...
Arvinas and Pfizer are the first to take a PROteolysis TArgeting Chimera (PROTAC) therapy across the FDA finish line, opening ...
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still searching for ...
Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...
Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit ...
The FDA has approved Pfizer and Arvinas’ Veppanu, the first proteolysis-targeting chimera (PROTAC) therapy, for advanced ER-positive, HER2-negative breast cancer with ESR1 mutations after prior ...
Vepdegestrant introduces a novel mechanism in oncology: targeted protein degradation to remove cancer-driving proteins. This approach may overcome endocrine resistance, a key challenge in advanced ...
This article and associated images are based on a poster originally authored by Kieran Casey, Yuzhou Xu, Jichuan Zhang, Shuyue Wang, Yanfei Hu, Ye Tian, Min Lyu, Ziyu Chen, Ya Xu, Qikuan Chen and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results